Literature DB >> 2031341

Inactivation of lipid-enveloped viruses in proteins by caprylate.

J L Lundblad1, R L Seng.   

Abstract

The use of caprylate for the inactivation of lipid-enveloped viruses in biologically active proteins both plasma derived and produced by cell culture was evaluated. Viruses consisted of herpes simplex virus type I, vesicular stomatitis virus, vaccinia virus, and Sindbis virus. Utilizing the dissociation reaction and varying the concentration of the ionized form of caprylate, a specific amount of the nonionized form of caprylate was maintained over a wide pH range. Virus-spiked protein solutions contacted with caprylate provide rapid virus inactivation under a variety of conditions while maintaining the integrity of the respective protein or activity. With the exception of coagulation factor AHF, protein and biological activity yield were essentially quantitative. Caprylate is removed after treatment by size exclusion chromatography or anion/cation exchange adsorption of the protein, followed by buffer wash.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2031341     DOI: 10.1111/j.1423-0410.1991.tb00878.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  7 in total

1.  Oleic acid inhibits stearic acid-induced inhibition of cell growth and pro-inflammatory responses in human aortic endothelial cells.

Authors:  Kevin A Harvey; Candace L Walker; Zhidong Xu; Phillip Whitley; Thomas M Pavlina; Mary Hise; Gary P Zaloga; Rafat A Siddiqui
Journal:  J Lipid Res       Date:  2010-09-17       Impact factor: 5.922

2.  Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.

Authors:  Caroline Goussen; Steve Simoneau; Soline Bérend; Christine Jehan-Kimmel; Anne Bellon; Céline Ducloux; Bruno You; Philippe Paolantonacci; Monique Ollivier; Ludovic Burlot; Sami Chtourou; Benoît Flan
Journal:  BioDrugs       Date:  2017-06       Impact factor: 5.807

3.  Evaluation of the effectiveness of the SurePure Turbulator ultraviolet-C irradiation equipment on inactivation of different enveloped and non-enveloped viruses inoculated in commercially collected liquid animal plasma.

Authors:  Elena Blázquez; Carmen Rodríguez; Jesús Ródenas; Núria Navarro; Cristina Riquelme; Rosa Rosell; Joy Campbell; Joe Crenshaw; Joaquim Segalés; Joan Pujols; Javier Polo
Journal:  PLoS One       Date:  2019-02-21       Impact factor: 3.240

Review 4.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 5.  Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Authors:  Kang Cai; Todd M Gierman; JoAnn Hotta; Christopher J Stenland; Douglas C Lee; Dominique Y Pifat; Steve R Petteway
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807

Review 6.  Assessment of the viral safety of antivenoms fractionated from equine plasma.

Authors:  Thierry Burnouf; Elwyn Griffiths; Ana Padilla; Salwa Seddik; Marco Antonio Stephano; José-María Gutiérrez
Journal:  Biologicals       Date:  2004-09       Impact factor: 1.856

7.  Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process.

Authors:  C P Caricati; L Oliveira-Nascimento; J T Yoshida; A T P Caricati; I Raw; M A Stephano
Journal:  Biotechnol Prog       Date:  2013-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.